Group 1 - The announcement is regarding the third advisory notice of the voluntary tender offer by Ningbo Meishan Bonded Port Area Jincheng Shazhou Equity Investment Co., Ltd. for shares of Fushun Special Steel Co., Ltd. [1] - The tender offer is valid from August 12, 2025, to September 10, 2025, with the last three trading days being September 8, 9, and 10, during which shareholders cannot withdraw their acceptance of the offer [2][8] - The number of shares to be acquired is 98,605,000, representing 5% of the total share capital of Fushun Special Steel, at a price of 5.60 yuan per share [2][4] Group 2 - The offer price of 5.60 yuan per share is based on the weighted average price of Fushun Special Steel's shares over the last 30 trading days, which was 5.36 yuan per share [2] - The purpose of the tender offer is to increase the holding ratio in the listed company, consolidate control, and enhance the stability of the company's equity structure [2][5] - The total maximum funds required for the tender offer amount to 552,188,000 yuan, which will be sourced from the acquirer's own and self-raised funds [7] Group 3 - The tender offer is classified as a voluntary offer and is not a fulfillment of statutory tender offer obligations [6] - The acquisition does not aim to terminate the listing status of the company, and the share distribution will still comply with the listing conditions of the Shanghai Stock Exchange [5] - As of September 2, 2025, the total number of shares accepted for the tender offer is 839,800, accounting for approximately 0.043% of the total share capital [28]

Core Viewpoint - The announcement serves as the third reminder regarding the tender offer by Ningbo Meishan Bonded Port Area Jincheng Shazhou Equity Investment Co., Ltd. to acquire shares of Fushun Special Steel Co., Ltd. [1] Group 1: Tender Offer Details - The tender offer is valid from August 12, 2025, to September 10, 2025, with the last three trading days being September 8, 9, and 10, during which shareholders cannot withdraw their acceptance of the offer [2][4] - The offer price is set at 5.60 yuan per share, which is not lower than the highest price paid by the acquirer for the shares in the last six months prior to the announcement [2][3] - The total maximum funds required for the acquisition, based on the offer price and the number of shares to be acquired (98,605,000 shares), amounts to 552,188,000 yuan [3][4] Group 2: Purpose and Strategy - The purpose of the tender offer is to increase the acquirer's shareholding in the company, consolidate control, and enhance the stability of the company's equity structure [2][3] - The acquirer aims to leverage its resources to introduce more strategic and business resources to the company, facilitating its long-term and healthy development in the special steel and alloy materials market [2][3] Group 3: Funding and Compliance - The funds for the acquisition will come from the acquirer's own and self-raised funds, with a bank guarantee already submitted to ensure the fulfillment of the tender offer [3][4] - The tender offer does not aim to terminate the company's listing status, and the share distribution post-offer will still comply with the listing conditions of the Shanghai Stock Exchange [3][4] Group 4: Acceptance and Withdrawal Procedures - Shareholders can submit their acceptance of the tender offer through their securities companies during the trading hours within the offer period [5][6] - Shareholders can withdraw their acceptance of the tender offer during the offer period, but not during the last three trading days [8][6] Group 5: Additional Information - As of September 2, 2025, the total number of shares accepted for the tender offer will be disclosed, and further details can be found in the tender offer report published on August 7, 2025 [7][8]

Summary of Key Points Core Viewpoint - The acquisition of Hubei Jichuan Pharmaceutical Co., Ltd. by Cao Fei through Jichuan Holdings is a strategic move that complies with legal requirements, ensuring the company's continued operation and governance integrity [1][2]. Group 1: Acquisition Overview - Cao Fei acquired 10.10% of Jichuan Holdings for 10.1 million yuan, resulting in a 60% ownership stake in Jichuan Holdings, which indirectly controls 516,757,360 shares of Jichuan Pharmaceutical, representing 56.07% of the total share capital [1][2]. - The acquisition triggered a mandatory tender offer due to holding over 30% of the company's shares, aimed at fulfilling legal obligations rather than delisting the company [2]. Group 2: Tender Offer Details - The initial offer price was set at 26.93 yuan per share, later adjusted to 24.85 yuan based on the 2024 profit distribution plan, with a tender offer period from June 18, 2025, to July 17, 2025 [3]. - By the end of the tender offer period, only 34 shareholders accepted the offer, totaling 16,300 shares, which is 0.0018% of the total share capital [3]. Group 3: Post-Acquisition Shareholding Structure - After the acquisition, Cao Fei directly holds 16,300 shares and indirectly controls 516,773,660 shares, maintaining a 56.07% stake in the company [4]. - The combined control of Cao Fei and his associate Cao Longxiang amounts to 61.15% of the total share capital, ensuring compliance with listing requirements [4]. Group 4: Compliance and Governance - During the continuous supervision period, Cao Fei and associates adhered to legal and regulatory requirements, ensuring proper governance and independent operation of Jichuan Pharmaceutical [5]. - The company has improved its governance structure and information disclosure practices, aligning with regulatory standards [5]. Group 5: Commitments and Future Plans - Commitments were made to reduce and regulate related party transactions, avoid competition, and maintain the independence of the company’s operations [6][7]. - No plans were disclosed for significant changes to the company's main business, asset sales, mergers, management adjustments, or amendments to the company’s articles of association within the next 12 months [8][9][10]. Group 6: Financial Integrity - There were no violations regarding the provision of guarantees or loans to the acquirer or related parties that could harm the interests of Jichuan Pharmaceutical [11]. - The financial advisor confirmed that all actions taken during the supervision period were compliant with regulations and did not violate any commitments [11].

Core Viewpoint - Shenzhen Huili Hongsheng Industrial Holdings (Limited Partnership) has completed a tender offer for Shinke Bearings Co., Ltd., acquiring 14,565,471 shares, which is 9.71% of the total share capital, and will become the controlling shareholder after the transfer of additional shares [1][5]. Group 1: Tender Offer Details - The tender offer price was set at 16.13 CNY per share for a total of 86,587,534 shares, representing 57.73% of the company's total issued shares [2][3]. - The tender offer was initiated to fulfill the legal obligation of a comprehensive tender offer due to Shenzhen Huili acquiring 41.89% of the shares from the previous controlling shareholders [2][3]. Group 2: Shareholder Impact - Following the completion of the tender offer, Shenzhen Huili will hold a total of 51.60% of Shinke Bearings' shares after the transfer of the additional 41.89% shares [5]. - The tender offer does not aim to terminate the listing status of Shinke Bearings, and the share distribution will still comply with the listing conditions of the Shenzhen Stock Exchange [1][5]. Group 3: Stock Resumption - Shinke Bearings' stock will resume trading on September 2, 2025, after the confirmation of the tender offer results [5][6]. - Shenzhen Huili has committed not to reduce its holdings in Shinke Bearings for 18 months following the completion of the tender offer [5].

Core Viewpoint - The financial advisor, Shenwan Hongyuan Securities, is overseeing the tender offer by Beijing Zhichuang Tiandi Technology Development Co., Ltd. for Chongqing Wanli New Energy Co., Ltd., with a focus on compliance and operational integrity during the acquisition process [1][2]. Summary by Sections Tender Offer Execution - The tender offer involves acquiring 30,657,480 shares, representing 20.00% of the total share capital of Wanli New Energy, at a price of 7.00 CNY per share, with the offer period from August 6, 2024, to September 4, 2024 [1]. Compliance and Governance - During the ongoing supervision period, Wanli New Energy has adhered to the regulations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange, establishing a sound corporate governance structure and internal control system [2][3]. Public Commitment Fulfillment - Zhichuang Tiandi has made commitments to maintain the independence of Wanli New Energy, avoid competition, and regulate related party transactions, with no violations reported during the supervision period [2][3]. Post-Acquisition Plans - There are no plans to change the main business operations, dispose of significant assets, or alter the management structure within the next 12 months, ensuring stability in operations [4][5][6]. Employee and Dividend Policies - No significant changes to employee hiring practices or dividend policies are planned, indicating a commitment to maintaining current operational practices [6][7]. Summary of Continuous Supervision - The financial advisor concludes that Wanli New Energy has fulfilled its obligations regarding the tender offer, and both the acquirer and the target company have operated in compliance with relevant regulations without any detrimental actions against the company's interests [7].

Overview - The company has proposed to the shareholders' meeting to approve the exemption of the controlling shareholder, Maoming Port Group Co., Ltd., from making a mandatory tender offer following a specific stock issuance [1][2] Group 1: Proposal Details - The company plans to issue 155,962,606 shares to Maoming Port, which will result in the controlling shareholder exceeding 30% of the voting rights in the company [1] - The issuance is subject to approval by the shareholders' meeting, where related shareholders will abstain from voting [2] Group 2: Regulatory Framework - According to the "Measures for the Administration of the Acquisition of Listed Companies," investors can be exempt from making a tender offer if approved by non-related shareholders and commit to not transferring the newly issued shares for three years [2] - Maoming Port has committed to not transferring the shares acquired in this issuance for 36 months from the completion of the issuance [2]

Core Viewpoint - The announcement details the results of the shareholding increase plan by the controlling shareholder of Anhui Anfu Battery Technology Co., Ltd., which has been nearly completed but is now terminated to avoid triggering mandatory tender offer obligations [2][3][7]. Summary by Sections Shareholding Increase Plan - The controlling shareholder, Shenzhen Qianhai Glory Capital Management Co., Ltd., initially planned to increase its shareholding by no less than RMB 300 million, later raising the amount to RMB 500 million [2][4]. - As of the announcement date, the total amount of shares purchased by the controlling shareholder reached RMB 335.33 million, completing 98.79% of the planned increase [2][4]. Termination of the Plan - The increase in shareholding was terminated because the controlling shareholder's voting rights reached 29.98%, and further increases would trigger mandatory tender offer obligations under the regulations [3][7]. - The decision to terminate the plan was based on objective regulatory constraints rather than issues related to funding or commitment [7]. Future Outlook - Despite the termination of the shareholding increase plan, the controlling shareholder maintains confidence in the company's core competitiveness and long-term investment value, indicating ongoing support through strategic collaboration [7][8].

Group 1 - The core point of the announcement is that Anfu Technology's controlling shareholder, Qianhai Glory, has completed 98.79% of its share buyback plan, amounting to 335.33 million yuan [1] - As of August 26, 2023, the shareholding of Qianhai Glory and its concerted parties has reached 29.98%, which is close to the 30% threshold that would trigger a mandatory tender offer [1] - Qianhai Glory has decided to terminate its share buyback plan to avoid exceeding the 30% voting rights threshold, which would obligate them to make a tender offer [1] Group 2 - For the fiscal year 2024, Anfu Technology's revenue composition is as follows: battery manufacturing sales account for 89.24%, agency business accounts for 10.62%, and other businesses account for 0.14% [1] - The current market capitalization of Anfu Technology is 8 billion yuan [2]

Core Viewpoint - The company is seeking shareholder approval for Jiangxi Maitong Health Beverage Development Co., Ltd. and its concerted actions to be exempt from making a mandatory tender offer following a share issuance and cash payment transaction [1][2]. Group 1: Shareholding and Transaction Details - As of April 30, 2025, the controlling shareholder, Jiangxi Provincial Tourism Group Co., Ltd. (Jiangxi Group), and its concerted party, Nanchang Jiangxi Asset Management Co., Ltd., collectively hold 24.30% of the company's shares [1]. - The company plans to acquire 100% of Jiangxi Runtian Industrial Co., Ltd. through a combination of issuing shares and cash payments to Jiangxi Maitong, Jiangxi Runtian Investment Management Co., Ltd., and Nanchang Jinkai Capital Management Co., Ltd. [1]. - Jiangxi Maitong, a wholly-owned subsidiary controlled by Jiangxi Group, will subscribe for shares issued by the company as part of this transaction [1]. Group 2: Regulatory Compliance and Shareholder Approval - According to Article 63, Clause 1, Item (3) of the "Measures for the Administration of the Acquisition of Listed Companies," investors can be exempt from making a tender offer if they acquire new shares that exceed 30% of the company's issued shares, provided they commit not to transfer these shares for three years and receive approval from the shareholder meeting [2]. - Jiangxi Maitong has committed not to transfer the newly issued shares for 36 months, and the board of directors is requesting shareholder approval for the exemption from the tender offer requirement [2]. - The proposal will be submitted to the company's shareholder meeting for approval, requiring a two-thirds majority vote from non-related shareholders present at the meeting [2].

Group 1 - The acquisition involves Shuangrun Zheng'an Information Consulting (Beijing) Co., Ltd. making a partial tender offer for Jiangsu Haobio Pharmaceutical Co., Ltd. [1][2] - The tender offer includes 15,570,480 shares, representing 25.01% of the total shares after excluding repurchased shares, at a price of 33.74 CNY per share [2][3] - The tender offer period is set from December 24, 2024, to January 22, 2025, lasting for 30 calendar days [2] Group 2 - The financial advisor confirms that during the ongoing supervision period, Haobio and Shuangrun Zheng'an have complied with relevant regulations and operated in accordance with corporate governance standards [3][6] - Shuangrun Zheng'an and its concerted parties have committed to maintaining the operational independence of Haobio and ensuring no interference in its management [4][5] - There are no plans to change Haobio's main business or make significant adjustments within the next 12 months [7][8] Group 3 - The acquisition parties have committed to avoiding any competition with Haobio's main business and ensuring fair treatment in any necessary related transactions [5][6] - There are no plans for significant changes to the current board of directors or senior management of Haobio following the acquisition [9][10] - The financial advisor has verified that there are no plans for major changes to employee hiring or dividend policies within the next 12 months [11][12] Group 4 - The acquisition does not involve any guarantees or loans that could harm Haobio's interests [13] - The parties involved have fulfilled all other obligations stipulated in the acquisition agreement [13]